Breye Therapeutics

Structure of the eye
#Breye Therapeutics #Financing #Ophthalmology #Retinal diseases

Breye raises €67.5 million for retinal disease therapies

Breye Therapeutics has closed an over-subscribed €67.5 million Series A financing round.   The round was co-led by new investor Mission BioCapital and existing investor Novo Holdings, with participation from existing investor Sound Bioventures and additional new investors including the Ljungström family office, Innovestor Life Science, EIFO, Catalyze… Read More

#Business & Investment #News

Diabetic eye disease
#Breye Therapeutics #Diabetes #Diabetic macular oedema #Ophthalmology #Phase I trial

Phase Ib trial complete in patients with diabetic retinopathy

Breye Therapeutics is a clinical-stage ophthalmology focused biopharmaceutical company developing oral therapeutics for the early treatment of vascular eye diseases. The company has now completed its Phase Ib clinical trial evaluating its lead candidate, danegaptide, in patients with non-proliferative diabetic retinopathy (NPDR) with associated oedema. Read More

#News